Strategikon Pharma
Analysis Budgeting, Forecasting, and Outsourcing Solutions for Clinical Trials
ViiV Healthcare has reported that the Phase III ATLAS-2M clinical trial of its long-acting, two-drug regimen developed to treat HIV infection met its primary endpoint.
ViiV Healthcare has reported that the Phase III ATLAS-2M clinical trial of its long-acting, two-drug regimen developed to treat HIV infection met its primary endpoint.
The regimen comprises ViiV’s cabotegravir and Janssen’s rilpivirine.
ATLAS-2M compared the antiviral activity and safety of the long-acting regimen given every eight weeks to the regimen given every four weeks. The 48-week study enrolled HIV-1 patients with suppressed viral load and no resistance to either drug.
According to the headline results, the long-acting regimen showed non-inferiority at week 48 to cabotegravir and rilpivirine administered every four weeks.
Non-inferiority was determined by comparing the proportions of patients having plasma HIV-RNA ≥50 copies per millilitre with the FDA Snapshot algorithm.
The overall safety, virologic response and drug resistance data for the every eight-week, long-acting regimen was found to be consistent with that observed in the Phase III ATLAS trial.
ViiV Healthcare Research & Development head Kimberly Smith said: “We are excited to report that for the first time since the AIDS epidemic started more than 30 years ago, our ATLAS-2M study has demonstrated that it is possible to maintain suppression of the HIV virus with an injectable regimen containing two drugs administered every two months.
“The ATLAS-2M study results mean that people living with HIV could maintain viral suppression with six total treatments per year, instead of a daily oral treatment 365 times per year.”
ATLAS-2M is part of ViiV’s clinical trial programme for two-drug regimens.
GlobalData's TMT Themes 2021 Report tells you everything you need to know about disruptive tech themes and which companies are best placed to help you digitally transform your business.
Find out moreThe Phase III randomised, open-label, active-controlled, multi-centre, parallel-group study is being performed in 13 countries including the US, Canada, and Australia.
In the US, Canada, and Europe, the company is seeking regulatory approval for the long-acting, injectable regimen of cabotegravir and rilpivirine to treat patients with HIV.
Analysis Budgeting, Forecasting, and Outsourcing Solutions for Clinical Trials
Patient-Centric Services for In-Home or Alternate-Site Clinical Trials Settings
Electronic Data Capture Solutions for Clinical Trials